Clinical Trial

CAR-T Combined With ASCT in the Treatment of Relapsed/Refractory Large B-cell Lymphoma With High-risk Factors.

Study acronym: CAR-T+ASCT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, single-center, open-label clinical study, aiming to evaluate the efficacy and safety of CAR-T combined with ASCT in the treatment of relapsed/refractory large B-cell lymphoma with high-risk factors.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-14
Trial Details
NCT Number NCT07538635
Lead Sponsor Zhejiang Cancer Hospital
Conditions High-risk R/R LBCL
Enrollment 20 participants
Start Date 2026-04-20
Primary Completion 2028-02-29 (estimated)
Study Completion 2028-02-29 (estimated)
Updated on ClinicalTrials.gov 2026-05-13